Clinical trial
Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder
NCT03169816 is registered in ClinicalTrials.gov with New York State Psychiatric Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder
- Lead sponsor
- New York State Psychiatric Institute
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- May 25, 2017
- Completion date
- August 30, 2019
- Enrollment
- 60 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
opioid-use disorder